Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile

Abstract Glioblastoma is one of the most treatment-resistant and lethal cancers, with a subset of self-renewing brain tumour stem cells (BTSCs), driving therapy resistance and relapse. Here, we report that mubritinib effectively impairs BTSC stemness and growth. Mechanistically, bioenergetic assays...

Full description

Saved in:
Bibliographic Details
Main Authors: Audrey Burban, Cloe Tessier, Mathieu Larroquette, Joris Guyon, Cloe Lubiato, Mathis Pinglaut, Maxime Toujas, Johanna Galvis, Benjamin Dartigues, Emmanuelle Georget, H Artee Luchman, Samuel Weiss, David Cappellen, Nathalie Nicot, Barbara Klink, Macha Nikolski, Lucie Brisson, Thomas Mathivet, Andreas Bikfalvi, Thomas Daubon, Ahmad Sharanek
Format: Article
Language:English
Published: Springer Nature 2025-02-01
Series:EMBO Molecular Medicine
Subjects:
Online Access:https://doi.org/10.1038/s44321-025-00195-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items